Anticholinergic burden of patients with dementia attending a Psychiatry of Later Life service

Abstract

Objectives. Older adults with dementia are particularly vulnerable to adverse outcomes resulting from anticholinergic use. We aimed to: (i) Examine the anticholinergic burden of patients with dementia attending a Psychiatry of Later Life (PLL) service (ii) Examine concomitant prescription of acetylcholinesterase inhibitors (AChEIs) and anticholinergics and (iii) Compare the Anticholinergic Cognitive Burden (ACB) scale with a recently published composite list of anticholinergics. Methods. Retrospective chart review of new referrals with a diagnosis of dementia (n = 66) seen by the PLL service, Tallaght University Hospital, Dublin, Ireland, over a consecutive period of 4 months. Results. The mean ACB score was 2.2 (range = 0–9, SD = 2.1). 37.9% (n = 25) had a clinically significant ACB score (>3) and 42.1% (n = 8) of those taking AChEIs had a clinically significant ACB score. A significantly greater number of medications with anticholinergic activity were identified using the composite list versus the traditional ACB scale (2.3 v.1.5, p = 0.001). Conclusions. We demonstrated a significant anticholinergic burden amongst patients with dementia attending a specialist PLL service. There was no difference in anticholinergic burden between groups prescribed and not prescribed AChEIs, indicating that these medications are being prescribed without discontinuation of potentially inappropriate medications with anticholinergic activity. The true anticholinergic burden experienced by patients may be underestimated by the use of the ACB score alone, although the clinical significance of this finding is unclear. Calculation of true clinical anticholinergic burden load and its translation to a specific rating scale remains a challenge.

Anticholinergic Burden of Geriatric Ward Inpatients

“…In a study of 341 community-dwelling elderly in the USA, West et al reported that persons who had total ACB scores greater or equal to 3 made up 47.8% of the cohort [ 21 ], while Cebron Lipovec et al in 2020 reported that this same subset constituted 12.1% of their cohort [ 20 ]. Vaughan et al reported that 37.9% of hospitalized patients with dementia had ACB ≥ 3 or were prescribed one medication with an ACB of 2 or higher [ 22 ].…”